Monika Wroclawska
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial.
Journal: International journal of hematology
Published: December 17, 2023
Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 × 109/L to <100 × 109/L) at baseline: the final analysis of EXPAND.
Journal: Therapeutic advances in hematology
Published: March 08, 2022
Real-world non-interventional long-term post-authorisation safety study of ruxolitinib in myelofibrosis.
Journal: British journal of haematology
Published: January 16, 2020
Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.
Journal: The Lancet. Haematology
Published: March 08, 2019
EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis.
Journal: Haematologica
Published: August 16, 2018
Showing 1-8 of 8
Last Updated: 09/26/2026